Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1, Manufactured on the AGE1.CR.pIX Novel Avian Cell Line, in Healthy Adult Volunteers.

Next Previous
X
Search
Trial Profile

A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1, Manufactured on the AGE1.CR.pIX Novel Avian Cell Line, in Healthy Adult Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VTP 100 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Barinthus Biotherapeutics; Vaccitech

    • Most Recent Events

    • 23 May 2018 According to an Vaccitech media release, data were presented at the 2018 Annual Conference on Vaccinology Research.
    • 10 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 31 Oct 2017 Planned End Date changed from 19 Oct 2017 to 15 Nov 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top